The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Oct 6

PMID 27706242

Citations 11

Authors

Moo Hyun Lee

So-Youn Jung

Sun Hee Kang

Eun Jin Song

In Hae Park

Sun-Young Kong

Young Mee Kwon

Keun Seok Lee

Han-Sung Kang

Eun Sook Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: This study evaluated the association of serum HER2 (sHER2) levels at diagnosis with clinicopathologic parameters and disease free survival (DFS) in operable breast cancer patients according to intrinsic subtype.

Methods: The sHER2 levels were measured using a chemiluminescence immunoassay. The HER2 status in all tumor tissues was determined by immunohistochemistry, and confirmed in equivocal cases by fluorescence in situ.

Results: There were 436 consecutive stage I-III breast cancer patients with sHER2 result at diagnosis between Nov 2004 and Dec 2011. High sHER2 levels (≥ 15 ng/ml) were reported in 52 patients (11.9%) and HER2 overexpression in tumor tissue was observed in 111 patients (25.5%). High sHER2 levels were associated significantly with advanced stage (P < 0.001), mastectomy (P = 0.012), neoadjuvant chemotherapy (P < 0.001), anti-HER2 therapy (P < 0.001) and hormone therapy (P = 0.022). The patients with high sHER2 levels had a worse DFS (P < 0.001). In multivariate analysis, high sHER2 levels were associated significantly with worse DFS (HR = 2.25, 95% CI 1.27-3.99, P = 0.005). High sHER2 levels were associated with worse DFS in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes (P = 0.043, 0.003 and 0.041, respectively).

Conclusions: These results show that the sHER2 level at diagnosis is a useful prognostic factor in patients with operable breast cancer, especially in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes.

Citing Articles

Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.

Wang S, Chen Y, Li W, Hao C, Zhang L, Zhao W Breast Cancer (Dove Med Press). 2024; 16:163-179.

PMID: 38585222 PMC: 10999221. DOI: 10.2147/BCTT.S449510.

The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples.

Antos A, Topolska-Wos A, Wos M, Mitura A, Sarzynska P, Lipinski T Sci Rep. 2024; 14(1):3978.

PMID: 38368450 PMC: 10874376. DOI: 10.1038/s41598-024-54590-z.

Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis.

Wu Y, Li L, Zhang D, Ma F Cancers (Basel). 2022; 14(19).

PMID: 36230471 PMC: 9559205. DOI: 10.3390/cancers14194551.

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.

Mummareddy S, Pradhan S, Narasimhan A, Natarajan A Biosensors (Basel). 2021; 11(12).

PMID: 34940257 PMC: 8699359. DOI: 10.3390/bios11120500.

Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.

Zuo W, He M, Zheng H, Liu Y, Liu X, Jiang Y Gland Surg. 2021; 10(4):1300-1314.

PMID: 33968682 PMC: 8102211. DOI: 10.21037/gs-20-802.

References

Bramwell V, Doig G, Tuck A, Wilson S, Tonkin K, Tomiak A . Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat. 2008; 114(3):503-11. DOI: 10.1007/s10549-008-0033-2. View

Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F . Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 2012; 107(6):956-60. PMC: 3464767. DOI: 10.1038/bjc.2012.353. View

Molina M, Saez R, Ramsey E, Garcia-Barchino M, Rojo F, Evans A . NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002; 8(2):347-53. View

Harris L, Liotcheva V, Broadwater G, Ramirez M, Maimonis P, Anderson S . Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001; 19(6):1698-706. DOI: 10.1200/JCO.2001.19.6.1698. View

Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, SCHOLTEN C, Seifert M . Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology. 1997; 54(6):475-81. DOI: 10.1159/000227606. View

Hayes D, Yamauchi H, Broadwater G, Cirrincione C, Rodrigue S, Berry D . Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001; 7(9):2703-11. View

Christianson T, DOHERTY J, Lin Y, Ramsey E, Holmes R, Keenan E . NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998; 58(22):5123-9. View

Molina M, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J . Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001; 61(12):4744-9. View

Lee S, Lee J, Yu J, Ko B, Kim H, Son B . Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer. 2014; 14:929. PMC: 4295268. DOI: 10.1186/1471-2407-14-929. View

10.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

11.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

12.

Kong S, Lee D, Lee E, Park S, Lee K, Ro J . Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer. Cancer Res Treat. 2009; 38(1):35-9. PMC: 2741656. DOI: 10.4143/crt.2006.38.1.35. View

13.

Baselga J . Is circulating HER-2 more than just a tumor marker?. Clin Cancer Res. 2001; 7(9):2605-7. View

14.

Schwartz M, Smith C, Schwartz D, Dnistrian A, Neiman I . Monitoring therapy by serum HER-2/neu. Int J Biol Markers. 2001; 15(4):324-9. DOI: 10.1177/172460080001500409. View

15.

Mehta R, McDermott J, Hieken T, Marler K, Patel M, Wild L . Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol. 1998; 16(7):2409-16. DOI: 10.1200/JCO.1998.16.7.2409. View

16.

Carney W, Neumann R, Lipton A, Leitzel K, Ali S, Price C . Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003; 49(10):1579-98. DOI: 10.1373/49.10.1579. View

17.

Shou J, Massarweh S, Osborne C, Wakeling A, Ali S, Weiss H . Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96(12):926-35. DOI: 10.1093/jnci/djh166. View

18.

Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A . Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON. 2008; 13(3):409-13. View

19.

COOK G, Neaman I, Goldblatt J, Cambetas D, Hussain M, Luftner D . Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 2001; 21(2B):1465-70. View

20.

Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M . Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res. 2003; 23(2A):1043-50. View